Sonova Holding AG

LSE:0QPY Stock Report

Market Cap: CHF 15.3b

Sonova Holding Valuation

Is 0QPY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QPY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 377.76
Fair Value
31.9% undervalued intrinsic discount
19
Number of Analysts

Below Fair Value: 0QPY (CHF254.85) is trading below our estimate of fair value (CHF374.23)

Significantly Below Fair Value: 0QPY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QPY?

Key metric: As 0QPY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QPY. This is calculated by dividing 0QPY's market cap by their current earnings.
What is 0QPY's PE Ratio?
PE Ratio28.3x
EarningsCHF 540.50m
Market CapCHF 15.28b

Price to Earnings Ratio vs Peers

How does 0QPY's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QPY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.9x
SN. Smith & Nephew
32.4x16.35%UK£9.8b
NIOX NIOX Group
84.7x37.48%UK£298.0m
CTEC ConvaTec Group
43x17.22%UK£6.0b
EKF EKF Diagnostics Holdings
19.4xn/aUK£121.3m
0QPY Sonova Holding
28.3x10.91%CHF 15.2b

Price-To-Earnings vs Peers: 0QPY is good value based on its Price-To-Earnings Ratio (28.3x) compared to the peer average (44.9x).

Price to Earnings Ratio vs Industry

How does 0QPY's PE Ratio compare vs other companies in the European Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0QPY 28.3xIndustry Avg. 32.2xNo. of Companies10PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QPY is good value based on its Price-To-Earnings Ratio (28.3x) compared to the European Medical Equipment industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is 0QPY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QPY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.3x
Fair PE Ratio46.5x

Price-To-Earnings vs Fair Ratio: 0QPY is good value based on its Price-To-Earnings Ratio (28.3x) compared to the estimated Fair Price-To-Earnings Ratio (46.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QPY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 257.11
CHF 274.47
+6.75%
13.65%CHF 360.00CHF 189.00n/a19
May ’26CHF 252.00
CHF 287.95
+14.26%
12.08%CHF 360.00CHF 224.00n/a19
Apr ’26CHF 256.40
CHF 293.32
+14.40%
12.83%CHF 360.00CHF 224.00n/a19
Mar ’26CHF 289.12
CHF 298.94
+3.40%
14.18%CHF 375.00CHF 224.00n/a18
Feb ’26CHF 321.02
CHF 301.17
-6.18%
14.59%CHF 375.00CHF 224.00n/a18
Jan ’26CHF 294.90
CHF 301.33
+2.18%
14.48%CHF 375.00CHF 224.00n/a18
Dec ’25CHF 300.70
CHF 296.28
-1.47%
14.07%CHF 375.00CHF 224.00n/a18
Nov ’25CHF 316.60
CHF 292.78
-7.52%
12.44%CHF 350.00CHF 227.00n/a18
Oct ’25CHF 301.65
CHF 287.53
-4.68%
11.27%CHF 345.00CHF 227.00n/a17
Sep ’25CHF 295.67
CHF 286.06
-3.25%
11.01%CHF 335.00CHF 227.00n/a17
Aug ’25CHF 266.50
CHF 284.82
+6.88%
11.77%CHF 335.00CHF 220.00n/a17
Jul ’25CHF 279.95
CHF 284.82
+1.74%
11.77%CHF 335.00CHF 220.00n/a17
Jun ’25CHF 283.46
CHF 279.12
-1.53%
12.57%CHF 335.00CHF 220.00CHF 259.3917
May ’25CHF 255.40
CHF 270.29
+5.83%
11.38%CHF 325.00CHF 200.00CHF 252.0017
Apr ’25CHF 261.14
CHF 270.65
+3.64%
11.99%CHF 325.00CHF 200.00CHF 256.4017
Mar ’25CHF 276.15
CHF 270.59
-2.01%
13.44%CHF 325.00CHF 200.00CHF 289.1217
Feb ’25CHF 279.07
CHF 267.06
-4.30%
14.65%CHF 325.00CHF 200.00CHF 321.0216
Jan ’25CHF 273.42
CHF 257.07
-5.98%
12.69%CHF 320.00CHF 200.00CHF 294.9015
Dec ’24CHF 255.23
CHF 259.75
+1.77%
13.36%CHF 340.00CHF 200.00CHF 300.7016
Nov ’24CHF 217.35
CHF 249.50
+14.79%
15.75%CHF 340.00CHF 195.00CHF 316.6016
Oct ’24CHF 216.90
CHF 252.81
+16.56%
16.33%CHF 340.00CHF 195.00CHF 301.6516
Sep ’24CHF 229.25
CHF 253.59
+10.62%
15.43%CHF 331.00CHF 195.00CHF 295.6717
Aug ’24CHF 242.32
CHF 253.59
+4.65%
15.43%CHF 331.00CHF 195.00CHF 266.5017
Jul ’24CHF 238.60
CHF 254.76
+6.77%
14.83%CHF 331.00CHF 195.00CHF 279.9517
Jun ’24CHF 235.88
CHF 248.91
+5.52%
14.61%CHF 320.00CHF 180.30CHF 283.4618
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
CHF 275.24
Fair Value
6.6% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/06 23:25
End of Day Share Price 2025/06/06 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sonova Holding AG is covered by 41 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander KlebanBarclays
Hassan Al-WakeelBarclays
Thomas JonesBerenberg